Identification

Name
Buspirone
Accession Number
DB00490  (APRD00222)
Type
Small Molecule
Groups
Approved, Investigational
Description

An anxiolytic agent and a serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the benzodiazepines, but it has an efficacy comparable to diazepam. [PubChem]

Structure
Thumb
Synonyms
  • 8-(4-(4-(2-Pyrimidinyl)-1-piperizinyl)butyl)-8-azaspiro(4,5)decane-7,9-dione
  • Buspiron
  • Buspirona
  • Buspirone
  • Buspironum
External IDs
BCI-024 / MJ 90221-1
Product Ingredients
IngredientUNIICASInChI Key
Buspirone Hydrochloride207LT9J9OC33386-08-2RICLFGYGYQXUFH-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Buspar Tab 10mgTablet10 mgOralBristol Myers Squibb1989-12-312010-11-12Canada
BuspironeTablet10 mgOralSanis Health Inc2016-02-17Not applicableCanada
Buspirone-10 - Tab 10mgTablet10 mgOralPro Doc Limitee1997-01-15Not applicableCanada
BustabTablet10 mgOralValeant Canada Lp Valeant Canada S.E.C.1997-05-272014-07-30Canada
BustabTablet5 mgOralValeant Canada Lp Valeant Canada S.E.C.1997-05-272014-07-30Canada
Co BuspironeTablet10 mgOralCobalt Laboratories2005-11-092012-08-02Canada
LinbuspironeTablet10 mgOralLinson Pharma Co.1996-12-312006-05-29Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-buspirone - Tab 10mgTablet10 mgOralApotex Corporation1996-12-31Not applicableCanada
BusparTablet5 mg/1OralDirectrx2016-05-03Not applicableUs
BuspironeTablet10 mg/1OralStat Rx USA2002-03-012018-02-08Us
Buspirone HClTablet15 mg/1OralAmerincan Health Packaging2017-04-15Not applicableUs
Buspirone HClTablet5 mg/1OralTYA Pharmaceuticals2001-03-28Not applicableUs
Buspirone HClTablet10 mg/1OralImpax Generics2001-03-282016-11-15Us
Buspirone HClTablet10 mg/1OralRebel Distributors2001-03-28Not applicableUs
Buspirone HClTablet15 mg/1OralAmerincan Health Packaging2013-05-282015-12-29Us
busPIRone HClTablet30 mg/1OralAmneal Pharmaceuticals2017-05-24Not applicableUs
Buspirone HClTablet15 mg/1OralActavis Pharma Company2001-03-282019-03-31Us
International/Other Brands
Ansial (Rontag) / Anxiron (Valeant) / Anxut (Eisai) / Bespar / Buscalm (Wockhardt) / Busp (Hexal) / Buspar (Bristol-Myers Squibb) / Buspon (Deva) / Dalpas (Biotech) / Epsilat (Coup) / Pasrin (Aspen Pharmacare) / Spamilan (Anpharm)
Categories
UNII
TK65WKS8HL
CAS number
36505-84-7
Weight
Average: 385.5031
Monoisotopic: 385.247775261
Chemical Formula
C21H31N5O2
InChI Key
QWCRAEMEVRGPNT-UHFFFAOYSA-N
InChI
InChI=1S/C21H31N5O2/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20/h5,8-9H,1-4,6-7,10-17H2
IUPAC Name
8-{4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl}-8-azaspiro[4.5]decane-7,9-dione
SMILES
O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1

Pharmacology

Indication

For the management of anxiety disorders or the short-term relief of the symptoms of anxiety, and also as an augmention of SSRI-treatment against depression.

Structured Indications
Pharmacodynamics

Buspirone is used in the treatment of generalized anxiety where it has advantages over other antianxiety drugs because it does not cause sedation (drowsiness) and does not cause tolerance or physical dependence. Buspirone differs from typical benzodiazepine anxiolytics in that it does not exert anticonvulsant or muscle relaxant effects. It also lacks the prominent sedative effect that is associated with more typical anxiolytics. in vitro preclinical studies have shown that buspirone has a high affinity for serotonin (5-HT1A) receptors. Buspirone has no significant affinity for benzodiazepine receptors and does not affect GABA binding in vitro or in vivo when tested in preclinical models. Buspirone has moderate affinity for brain D2-dopamine receptors. Some studies do suggest that buspirone may have indirect effects on other neurotransmitter systems.

Mechanism of action

Buspirone binds to 5-HT type 1A serotonin receptors on presynaptic neurons in the dorsal raphe and on postsynaptic neurons in the hippocampus, thus inhibiting the firing rate of 5-HT-containing neurons in the dorsal raphe. Buspirone also binds at dopamine type 2 (DA2) receptors, blocking presynaptic dopamine receptors. Buspirone increases firing in the locus ceruleus, an area of brain where norepinephrine cell bodies are found in high concentration. The net result of buspirone actions is that serotonergic activity is suppressed while noradrenergic and dopaminergic cell firing is enhanced.

TargetActionsOrganism
A5-hydroxytryptamine receptor 1A
partial agonist
Human
AD(2) dopamine receptor
antagonist
Human
Absorption

Rapidly absorbed in man. Bioavailability is low and variable (approximately 5%) due to extensive first pass metabolism.

Volume of distribution
Not Available
Protein binding

95% (approximately 70% bound to albumin, 30% bound to alpha 1 -acid glycoprotein)

Metabolism

Metabolized hepatically, primarily by oxidation by cytochrome P450 3A4 producing several hydroxylated derivatives and a pharmacologically active metabolite, 1-pyrimidinylpiperazine (1-PP)

Route of elimination

In a single-dose study using 14C-labeled buspirone, 29% to 63% of the dose was excreted in the urine within 24 hours, primarily as metabolites; fecal excretion accounted for 18% to 38% of the dose.

Half life

2-3 hours (although the action of a single dose is much longer than the short halflife indicates).

Clearance
Not Available
Toxicity

Oral, rat LD50 = 136 mg/kg. Symptoms of overdose include dizziness, drowsiness, nausea or vomiting, severe stomach upset, and unusually small pupils.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe metabolism of Buspirone can be decreased when combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Experimental
2-mercaptobenzothiazoleThe metabolism of Buspirone can be decreased when combined with 2-mercaptobenzothiazole.Vet Approved
7-NitroindazoleThe risk or severity of adverse effects can be increased when Buspirone is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Buspirone.Experimental
AbirateroneThe serum concentration of Buspirone can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Aceprometazine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Acetophenazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Buspirone is combined with Adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Buspirone.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Buspirone is combined with Agomelatine.Approved, Investigational
AlaproclateBuspirone may increase the serotonergic activities of Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Buspirone is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Buspirone is combined with Alfentanil.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Buspirone is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Buspirone is combined with Almotriptan.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Buspirone is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Buspirone is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Buspirone.Approved, Illicit, Investigational
AmiodaroneThe metabolism of Buspirone can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Buspirone is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Buspirone.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Buspirone is combined with Amobarbital.Approved, Illicit
AmorolfineThe metabolism of Buspirone can be decreased when combined with Amorolfine.Approved, Investigational
AmoxapineBuspirone may increase the serotonergic activities of Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Buspirone is combined with Amperozide.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Buspirone.Approved, Illicit, Investigational
Amphotericin BThe metabolism of Buspirone can be decreased when combined with Amphotericin B.Approved, Investigational
AnidulafunginThe metabolism of Buspirone can be decreased when combined with Anidulafungin.Approved, Investigational
ApalutamideThe serum concentration of Buspirone can be decreased when it is combined with Apalutamide.Approved, Investigational
AprepitantThe serum concentration of Buspirone can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Buspirone is combined with Aripiprazole.Approved, Investigational
ArtemetherThe metabolism of Buspirone can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Buspirone is combined with Asenapine.Approved
AtazanavirThe metabolism of Buspirone can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Buspirone can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Azaperone.Investigational, Vet Approved
AzelastineBuspirone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Buspirone is combined with Baclofen.Approved
Bafilomycin A1The metabolism of Buspirone can be decreased when combined with Bafilomycin A1.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Buspirone is combined with Barbital.Illicit
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Buspirone.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Buspirone is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Benzocaine.Approved, Investigational
Benzoic AcidThe metabolism of Buspirone can be decreased when combined with Benzoic Acid.Approved, Investigational
Benzyl alcoholThe risk or severity of adverse effects can be increased when Buspirone is combined with Benzyl alcohol.Approved
BetaxololThe metabolism of Buspirone can be decreased when combined with Betaxolol.Approved, Investigational
BifeprunoxThe risk or severity of adverse effects can be increased when Buspirone is combined with Bifeprunox.Investigational
BifonazoleThe metabolism of Buspirone can be decreased when combined with Bifonazole.Approved, Investigational
BoceprevirThe metabolism of Buspirone can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Buspirone can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Buspirone can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Buspirone.Approved
Brefeldin AThe metabolism of Buspirone can be decreased when combined with Brefeldin A.Experimental
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Buspirone.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Buspirone is combined with Brexpiprazole.Approved, Investigational
BrigatinibThe serum concentration of Buspirone can be decreased when it is combined with Brigatinib.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Buspirone.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Buspirone.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Buspirone is combined with Bromazepam.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Buspirone is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Buspirone is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Buspirone is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Buspirone is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Buspirone is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Bupivacaine.Approved, Investigational
BuprenorphineBuspirone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Buspirone can be decreased when combined with Bupropion.Approved
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Buspirone.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Buspirone is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Buspirone is combined with Butamben.Approved
ButaperazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Butaperazine.Experimental
ButenafineThe metabolism of Buspirone can be decreased when combined with Butenafine.Approved
ButethalThe risk or severity of adverse effects can be increased when Buspirone is combined with Butethal.Approved, Illicit
ButoconazoleThe metabolism of Buspirone can be decreased when combined with Butoconazole.Approved
ButorphanolThe risk or severity of adverse effects can be increased when Buspirone is combined with Butorphanol.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Buspirone.Approved
CandicidinThe metabolism of Buspirone can be decreased when combined with Candicidin.Withdrawn
CanertinibThe risk or severity of adverse effects can be increased when Buspirone is combined with Canertinib.Investigational
Capric acidThe metabolism of Buspirone can be decreased when combined with Capric acid.Experimental
CarbamazepineThe metabolism of Buspirone can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Buspirone is combined with Carbinoxamine.Approved
CarbomycinThe metabolism of Buspirone can be decreased when combined with Carbomycin.Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Buspirone is combined with Carfentanil.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Cariprazine.Approved, Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Buspirone is combined with Carisoprodol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Buspirone.Withdrawn
CaspofunginThe metabolism of Buspirone can be decreased when combined with Caspofungin.Approved
CelecoxibThe metabolism of Buspirone can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Buspirone can be increased when it is combined with Ceritinib.Approved
CeruleninThe metabolism of Buspirone can be decreased when combined with Cerulenin.Approved
CetirizineThe risk or severity of adverse effects can be increased when Buspirone is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Buspirone is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Buspirone.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Chloroprocaine.Approved
ChloroquineThe metabolism of Buspirone can be decreased when combined with Chloroquine.Approved, Investigational, Vet Approved
ChloroxineThe metabolism of Buspirone can be decreased when combined with Chloroxine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Buspirone is combined with Chlorphenamine.Approved
ChlorproethazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Chlorproethazine.Experimental
ChlorpromazineThe metabolism of Buspirone can be decreased when combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Buspirone is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Buspirone can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CiclopiroxThe metabolism of Buspirone can be decreased when combined with Ciclopirox.Approved, Investigational
CimetidineThe metabolism of Buspirone can be decreased when combined with Cimetidine.Approved, Investigational
CinacalcetThe metabolism of Buspirone can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Cinchocaine.Approved, Vet Approved
CitalopramBuspirone may increase the serotonergic activities of Citalopram.Approved
ClarithromycinThe metabolism of Buspirone can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Buspirone can be decreased when combined with Clemastine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Buspirone is combined with Clidinium.Approved
ClobazamThe metabolism of Buspirone can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Buspirone is combined with clomethiazole.Investigational
ClomipramineBuspirone may increase the serotonergic activities of Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Buspirone is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Buspirone is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Buspirone is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Buspirone is combined with Clorazepate.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Buspirone is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Buspirone can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Buspirone can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Buspirone can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Buspirone can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Buspirone.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Buspirone.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Buspirone.Approved, Investigational
CordycepinThe metabolism of Buspirone can be decreased when combined with Cordycepin.Investigational
CrizotinibThe metabolism of Buspirone can be decreased when combined with Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Buspirone is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Buspirone is combined with Cyclobenzaprine.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Buspirone is combined with Cyclopropane.Experimental
CyclosporineThe metabolism of Buspirone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Buspirone is combined with Cyproheptadine.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Buspirone.Approved
DabrafenibThe serum concentration of Buspirone can be decreased when it is combined with Dabrafenib.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Buspirone is combined with Dantrolene.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Buspirone is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Buspirone.Investigational
DarifenacinThe metabolism of Buspirone can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Buspirone can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Buspirone can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Buspirone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Buspirone can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Buspirone is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Buspirone is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Buspirone is combined with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Buspirone is combined with Desloratadine.Approved, Investigational
DesvenlafaxineBuspirone may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Buspirone is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Buspirone is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Buspirone is combined with Dexmedetomidine.Approved, Vet Approved
DextromethorphanThe risk or severity of adverse effects can be increased when Buspirone is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Buspirone is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Buspirone is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Buspirone is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Buspirone is combined with Diazepam.Approved, Illicit, Investigational, Vet Approved
DichloropheneThe metabolism of Buspirone can be decreased when combined with Dichlorophene.Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Buspirone is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Buspirone is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Buspirone is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Buspirone.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Buspirone is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Buspirone is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Buspirone can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Buspirone is combined with Dimenhydrinate.Approved
DiphenhydramineThe metabolism of Buspirone can be decreased when combined with Diphenhydramine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Buspirone is combined with Diphenoxylate.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Dixyrazine.Experimental
DolasetronDolasetron may increase the serotonergic activities of Buspirone.Approved, Investigational
DoramectinThe risk or severity of adverse effects can be increased when Buspirone is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Buspirone can be decreased when combined with Dosulepin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Buspirone is combined with Doxepin.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Buspirone.Approved, Investigational
DoxycyclineThe metabolism of Buspirone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Buspirone.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Buspirone is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Buspirone.Approved, Illicit
DronedaroneThe metabolism of Buspirone can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Buspirone.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Buspirone is combined with Drotebanol.Experimental, Illicit
DuloxetineBuspirone may increase the serotonergic activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Buspirone is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Buspirone is combined with Ecgonine.Experimental, Illicit
EconazoleThe metabolism of Buspirone can be decreased when combined with Econazole.Approved
EcopipamThe risk or severity of adverse effects can be increased when Buspirone is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Buspirone.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Buspirone is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe metabolism of Buspirone can be decreased when combined with Efinaconazole.Approved
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Buspirone.Approved, Investigational
EliglustatThe metabolism of Buspirone can be decreased when combined with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Buspirone is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Buspirone is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Buspirone is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Buspirone can be decreased when it is combined with Enzalutamide.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Buspirone is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Buspirone is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Buspirone is combined with Ergotamine.Approved
ErythromycinThe metabolism of Buspirone can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramBuspirone may increase the serotonergic activities of Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Buspirone is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Buspirone.Approved, Investigational
EthanolBuspirone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Buspirone is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Buspirone is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Buspirone is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Buspirone is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Buspirone is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Buspirone is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Buspirone is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Buspirone is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Buspirone is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Buspirone is combined with Etomidate.Approved
EtoperidoneBuspirone may increase the serotonergic activities of Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Buspirone is combined with Etorphine.Illicit, Vet Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Buspirone.Approved
EzogabineThe risk or severity of adverse effects can be increased when Buspirone is combined with Ezogabine.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Buspirone is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Buspirone is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineBuspirone may increase the serotonergic activities of Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Buspirone is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenticonazoleThe metabolism of Buspirone can be decreased when combined with Fenticonazole.Experimental
FexofenadineThe risk or severity of adverse effects can be increased when Buspirone is combined with Fexofenadine.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Buspirone is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Buspirone can be decreased when combined with Fluconazole.Approved, Investigational
FlucytosineThe metabolism of Buspirone can be decreased when combined with Flucytosine.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Buspirone is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Buspirone is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Buspirone is combined with Flunitrazepam.Approved, Illicit
FluoxetineBuspirone may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Buspirone is combined with Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Buspirone is combined with Flurazepam.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Buspirone is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Buspirone is combined with Fluticasone propionate.Approved
FlutrimazoleThe metabolism of Buspirone can be decreased when combined with Flutrimazole.Experimental
FluvoxamineBuspirone may increase the serotonergic activities of Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Buspirone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Buspirone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Buspirone can be increased when combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Buspirone is combined with Fospropofol.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Buspirone is combined with Frovatriptan.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Buspirone.Approved, Investigational, Vet Approved
Fusidic AcidThe serum concentration of Buspirone can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Buspirone is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Buspirone is combined with Gabapentin Enacarbil.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Buspirone is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Buspirone is combined with Glutethimide.Approved, Illicit
GlyphosateThe metabolism of Buspirone can be decreased when combined with Glyphosate.Experimental
GranisetronGranisetron may increase the serotonergic activities of Buspirone.Approved, Investigational
GriseofulvinThe metabolism of Buspirone can be decreased when combined with Griseofulvin.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Buspirone is combined with Guanfacine.Approved, Investigational
HachimycinThe metabolism of Buspirone can be decreased when combined with Hachimycin.Experimental
HalazepamThe risk or severity of adverse effects can be increased when Buspirone is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe metabolism of Buspirone can be decreased when combined with Haloperidol.Approved
HaloproginThe metabolism of Buspirone can be decreased when combined with Haloprogin.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Buspirone is combined with Halothane.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Harmaline is combined with Buspirone.Experimental
HeroinThe risk or severity of adverse effects can be increased when Buspirone is combined with Heroin.Approved, Illicit, Investigational
HexetidineThe metabolism of Buspirone can be decreased when combined with Hexetidine.Approved, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Buspirone is combined with Hexobarbital.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Buspirone.Experimental
HydrocodoneBuspirone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Buspirone.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Buspirone.Approved
IdelalisibThe serum concentration of Buspirone can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Iloperidone.Approved
ImatinibThe metabolism of Buspirone can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Buspirone.Approved
IndalpineBuspirone may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Buspirone can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Buspirone is combined with Indiplon.Investigational
Ioflupane I-123Buspirone may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Buspirone.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Buspirone.Withdrawn
IsavuconazoleThe serum concentration of Buspirone can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Buspirone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Buspirone.Approved
IsoconazoleThe metabolism of Buspirone can be decreased when combined with Isoconazole.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Buspirone is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe metabolism of Buspirone can be decreased when combined with Isoniazid.Approved, Investigational
IsradipineThe metabolism of Buspirone can be decreased when combined with Isradipine.Approved, Investigational
ItraconazoleThe metabolism of Buspirone can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Buspirone can be increased when it is combined with Ivacaftor.Approved
JosamycinThe metabolism of Buspirone can be decreased when combined with Josamycin.Approved, Investigational
KetamineThe risk or severity of adverse effects can be increased when Buspirone is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Buspirone is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Buspirone can be decreased when combined with Ketoconazole.Approved, Investigational
KitasamycinThe metabolism of Buspirone can be decreased when combined with Kitasamycin.Experimental
L-TryptophanL-Tryptophan may increase the serotonergic activities of Buspirone.Approved, Nutraceutical, Withdrawn
LamotrigineThe risk or severity of adverse effects can be increased when Buspirone is combined with Lamotrigine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Buspirone.Approved
LevetiracetamThe risk or severity of adverse effects can be increased when Buspirone is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Buspirone is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Buspirone is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Buspirone is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Buspirone is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranBuspirone may increase the serotonergic activities of Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Buspirone is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Lidocaine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Buspirone is combined with Linezolid.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Buspirone is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Buspirone is combined with Lofentanil.Illicit
LopinavirThe metabolism of Buspirone can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Buspirone is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Buspirone is combined with Loratadine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Buspirone.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Buspirone is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Buspirone is combined with Lormetazepam.Approved
LorpiprazoleThe serum concentration of Buspirone can be increased when it is combined with Lorpiprazole.Approved
LovastatinThe metabolism of Buspirone can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Buspirone.Approved
LuliconazoleThe serum concentration of Buspirone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Buspirone can be increased when combined with Lumacaftor.Approved
LumefantrineThe metabolism of Buspirone can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Lurasidone.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Buspirone can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe metabolism of Buspirone can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Buspirone is combined with Maprotiline.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Buspirone.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Buspirone is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Buspirone is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Buspirone is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Buspirone is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Buspirone is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Melperone.Approved, Investigational
MepartricinThe metabolism of Buspirone can be decreased when combined with Mepartricin.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Buspirone.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Buspirone is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Buspirone is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Buspirone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Buspirone is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Buspirone is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Buspirone is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Buspirone.Approved
MethotrimeprazineBuspirone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Buspirone is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Buspirone is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Buspirone is combined with Methylecgonine.Experimental
Methylene blueBuspirone may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Buspirone is combined with Methylphenobarbital.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Buspirone is combined with Metoclopramide.Approved, Investigational
MetoprololThe metabolism of Buspirone can be decreased when combined with Metoprolol.Approved, Investigational
MetyrosineBuspirone may increase the sedative activities of Metyrosine.Approved
MevastatinThe metabolism of Buspirone can be decreased when combined with Mevastatin.Experimental
MicafunginThe metabolism of Buspirone can be decreased when combined with Micafungin.Approved, Investigational
MiconazoleThe metabolism of Buspirone can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe risk or severity of adverse effects can be increased when Buspirone is combined with Midazolam.Approved, Illicit
MidostaurinThe metabolism of Buspirone can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Buspirone can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranBuspirone may increase the serotonergic activities of Milnacipran.Approved, Investigational
MiltefosineThe metabolism of Buspirone can be decreased when combined with Miltefosine.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Buspirone.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Buspirone.Approved, Investigational
MirabegronThe metabolism of Buspirone can be decreased when combined with Mirabegron.Approved
MirtazapineBuspirone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Buspirone can be decreased when it is combined with Mitotane.Approved
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Buspirone.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Molindone.Approved
MonensinThe metabolism of Buspirone can be decreased when combined with Monensin.Vet Approved
MoperoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Moperone.Experimental
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Buspirone.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Buspirone is combined with Mosapramine.Experimental
MyxothiazolThe metabolism of Buspirone can be decreased when combined with Myxothiazol.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Buspirone.Approved, Investigational
NaftifineThe metabolism of Buspirone can be decreased when combined with Naftifine.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Buspirone is combined with Nalbuphine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Buspirone.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Buspirone is combined with Naratriptan.Approved, Investigational
NatamycinThe metabolism of Buspirone can be decreased when combined with Natamycin.Approved
NefazodoneBuspirone may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Buspirone can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Buspirone can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Buspirone can be increased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Buspirone.Withdrawn
NicardipineThe metabolism of Buspirone can be decreased when combined with Nicardipine.Approved, Investigational
NifuratelThe metabolism of Buspirone can be decreased when combined with Nifuratel.Experimental
Nikkomycin ZThe metabolism of Buspirone can be decreased when combined with Nikkomycin Z.Investigational
NilotinibThe metabolism of Buspirone can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Buspirone is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Buspirone is combined with Nitrous oxide.Approved, Vet Approved
NitroxolineThe metabolism of Buspirone can be decreased when combined with Nitroxoline.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Buspirone is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Buspirone is combined with Nortriptyline.Approved
NystatinThe metabolism of Buspirone can be decreased when combined with Nystatin.Approved, Vet Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Buspirone.Withdrawn
OlanzapineBuspirone may increase the serotonergic activities of Olanzapine.Approved, Investigational
OlaparibThe metabolism of Buspirone can be decreased when combined with Olaparib.Approved
OleandomycinThe metabolism of Buspirone can be decreased when combined with Oleandomycin.Vet Approved
OlopatadineThe risk or severity of adverse effects can be increased when Buspirone is combined with Olopatadine.Approved
OmoconazoleThe metabolism of Buspirone can be decreased when combined with Omoconazole.Experimental
OndansetronThe risk or severity of adverse effects can be increased when Buspirone is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Buspirone is combined with Opium.Approved, Illicit
OrphenadrineBuspirone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Buspirone is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Buspirone can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Buspirone is combined with Oxazepam.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Oxethazaine.Approved, Investigational
OxiconazoleThe metabolism of Buspirone can be decreased when combined with Oxiconazole.Approved
OxprenololThe risk or severity of adverse effects can be increased when Buspirone is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Buspirone is combined with Oxypertine.Experimental
PafuramidineThe metabolism of Buspirone can be decreased when combined with Pafuramidine.Investigational
PalbociclibThe serum concentration of Buspirone can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Buspirone.Approved, Investigational
PanobinostatThe serum concentration of Buspirone can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeBuspirone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Buspirone.Approved
ParoxetineBuspirone may increase the serotonergic activities of Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Buspirone.Approved
Peginterferon alfa-2bThe serum concentration of Buspirone can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Buspirone is combined with Penfluridol.Experimental
PentamidineThe metabolism of Buspirone can be decreased when combined with Pentamidine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Buspirone is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe metabolism of Buspirone can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Buspirone.Approved
PerazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Perazine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Buspirone.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Buspirone is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Buspirone.Approved
PhenibutThe risk or severity of adverse effects can be increased when Buspirone is combined with Phenibut.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Buspirone.Withdrawn
PhenobarbitalThe metabolism of Buspirone can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Buspirone is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Buspirone is combined with Phenoxyethanol.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Buspirone.Withdrawn
PhenytoinThe metabolism of Buspirone can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Buspirone is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Buspirone is combined with Piritramide.Approved, Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Buspirone.Approved
PitolisantThe serum concentration of Buspirone can be decreased when it is combined with Pitolisant.Approved, Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Buspirone.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Buspirone is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Buspirone is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Buspirone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleBuspirone may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Buspirone is combined with Prazepam.Approved, Illicit
PregabalinThe therapeutic efficacy of Buspirone can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Prilocaine.Approved
PrimidoneThe metabolism of Buspirone can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Buspirone.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Buspirone.Approved, Vet Approved
PromazineThe metabolism of Buspirone can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Promethazine.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Buspirone is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Proparacaine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Propericiazine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Buspirone is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Propoxycaine.Approved
ProthipendylThe risk or severity of adverse effects can be increased when Buspirone is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Buspirone.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Buspirone is combined with Proxibarbal.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Buspirone.Approved
PSD502The risk or severity of adverse effects can be increased when Buspirone is combined with PSD502.Investigational
PyrrolnitrinThe metabolism of Buspirone can be decreased when combined with Pyrrolnitrin.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Buspirone is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Buspirone is combined with Quetiapine.Approved
QuinidineThe metabolism of Buspirone can be decreased when combined with Quinidine.Approved, Investigational
QuinineThe metabolism of Buspirone can be decreased when combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Buspirone is combined with Raclopride.Investigational
RadicicolThe metabolism of Buspirone can be decreased when combined with Radicicol.Experimental
RamelteonThe risk or severity of adverse effects can be increased when Buspirone is combined with Ramelteon.Approved, Investigational
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Buspirone.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Buspirone.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Buspirone is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Buspirone is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Buspirone.Approved, Investigational
RibociclibThe serum concentration of Buspirone can be increased when it is combined with Ribociclib.Approved, Investigational
RifabutinThe serum concentration of Buspirone can be decreased when it is combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Buspirone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Buspirone can be decreased when it is combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Buspirone can be decreased when it is combined with Rifaximin.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Buspirone is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Buspirone is combined with Ritanserin.Investigational
RitonavirThe metabolism of Buspirone can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Buspirone is combined with Rizatriptan.Approved
RolapitantThe metabolism of Buspirone can be decreased when combined with Rolapitant.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Buspirone is combined with Romifidine.Vet Approved
RopiniroleBuspirone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Ropivacaine.Approved
RotigotineBuspirone may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Buspirone can be decreased when combined with Rucaparib.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Buspirone.Approved
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Buspirone.Withdrawn
Salicylhydroxamic AcidThe metabolism of Buspirone can be decreased when combined with Salicylhydroxamic Acid.Experimental
Salicylic acidThe metabolism of Buspirone can be decreased when combined with Salicylic acid.Approved, Investigational, Vet Approved
SaquinavirThe metabolism of Buspirone can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Buspirone can be decreased when used in combination with Sarilumab.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Buspirone is combined with Scopolamine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Buspirone.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Buspirone.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Buspirone is combined with Sepranolone.Investigational
SertaconazoleThe metabolism of Buspirone can be decreased when combined with Sertaconazole.Approved, Investigational
SertindoleThe risk or severity of adverse effects can be increased when Buspirone is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineBuspirone may increase the serotonergic activities of Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Buspirone is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Buspirone can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Buspirone.Approved
SiltuximabThe serum concentration of Buspirone can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Buspirone can be increased when it is combined with Simeprevir.Approved
SinefunginThe metabolism of Buspirone can be decreased when combined with Sinefungin.Experimental
SirolimusThe metabolism of Buspirone can be decreased when combined with Sirolimus.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Buspirone.Approved
SolithromycinThe metabolism of Buspirone can be decreased when combined with Solithromycin.Investigational
St. John's WortThe serum concentration of Buspirone can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Buspirone can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Buspirone is combined with Sufentanil.Approved, Investigational
SulconazoleThe metabolism of Buspirone can be decreased when combined with Sulconazole.Approved
SulfisoxazoleThe metabolism of Buspirone can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Buspirone is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Buspirone is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Buspirone is combined with Sumatriptan.Approved, Investigational
SuvorexantBuspirone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Buspirone.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Buspirone is combined with Tasimelteon.Approved, Investigational
TavaboroleThe metabolism of Buspirone can be decreased when combined with Tavaborole.Approved, Investigational
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Buspirone.Approved
TelaprevirThe metabolism of Buspirone can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Buspirone can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Buspirone.Approved, Investigational
TerbinafineThe metabolism of Buspirone can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerconazoleThe metabolism of Buspirone can be decreased when combined with Terconazole.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Tetrabenazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Buspirone is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Buspirone is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Buspirone is combined with Tetrodotoxin.Investigational
ThalidomideBuspirone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Buspirone is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Buspirone is combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Buspirone is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Thioproperazine.Approved
ThioridazineThe metabolism of Buspirone can be decreased when combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Buspirone is combined with Thiothixene.Approved
ThymolThe metabolism of Buspirone can be decreased when combined with Thymol.Approved
TiagabineThe risk or severity of adverse effects can be increased when Buspirone is combined with Tiagabine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Buspirone is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Buspirone can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Buspirone is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Buspirone is combined with Tilidine.Experimental
TioconazoleThe metabolism of Buspirone can be decreased when combined with Tioconazole.Approved
TipranavirThe metabolism of Buspirone can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Buspirone is combined with Tizanidine.Approved, Investigational
TocilizumabThe serum concentration of Buspirone can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Buspirone is combined with Tolcapone.Approved, Withdrawn
TolciclateThe metabolism of Buspirone can be decreased when combined with Tolciclate.Experimental
TolnaftateThe metabolism of Buspirone can be decreased when combined with Tolnaftate.Approved, Investigational, Vet Approved
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Buspirone.Approved
TopiramateThe risk or severity of adverse effects can be increased when Buspirone is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Buspirone.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Buspirone.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Buspirone.Approved, Investigational
TrazodoneBuspirone may increase the serotonergic activities of Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Buspirone is combined with Triazolam.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Buspirone is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Buspirone is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Trifluoperazine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Buspirone is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Triflupromazine.Approved, Vet Approved
TrimetrexateThe metabolism of Buspirone can be decreased when combined with Trimetrexate.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Buspirone is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Buspirone is combined with Triprolidine.Approved
TropisetronTropisetron may increase the serotonergic activities of Buspirone.Approved, Investigational
TylosinThe metabolism of Buspirone can be decreased when combined with Tylosin.Vet Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Buspirone is combined with Valproic Acid.Approved, Investigational
VemurafenibThe serum concentration of Buspirone can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineBuspirone may increase the serotonergic activities of Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Buspirone is combined with Veralipride.Experimental
VerapamilThe metabolism of Buspirone can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Buspirone is combined with Vigabatrin.Approved
VilazodoneBuspirone may increase the serotonergic activities of Vilazodone.Approved
VincristineThe excretion of Vincristine can be decreased when combined with Buspirone.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Buspirone is combined with Vinyl ether.Experimental
VoriconazoleThe metabolism of Buspirone can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineBuspirone may increase the serotonergic activities of Vortioxetine.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Buspirone is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Buspirone is combined with Xylazine.Vet Approved
YohimbineThe therapeutic efficacy of Buspirone can be decreased when used in combination with Yohimbine.Approved, Investigational, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Buspirone is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Buspirone is combined with Ziconotide.Approved
ZimelidineBuspirone may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Buspirone can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Buspirone is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Buspirone.Approved, Investigational
ZolpidemBuspirone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Buspirone is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Buspirone is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Buspirone is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Buspirone is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Always take at the same time with respect to meals.
  • Avoid alcohol.
  • Avoid taking grapefruit or grapefruit juice throughout treatment.
  • Take with food.

References

Synthesis Reference
US3717634
General References
Not Available
External Links
Human Metabolome Database
HMDB0014633
KEGG Compound
C06861
PubChem Compound
2477
PubChem Substance
46508113
ChemSpider
2383
BindingDB
50001859
ChEBI
3223
ChEMBL
CHEMBL49
Therapeutic Targets Database
DAP000031
PharmGKB
PA448689
IUPHAR
36
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Buspirone
ATC Codes
N05BE01 — Buspirone
AHFS Codes
  • 28:24.92 — Miscellaneous Anxiolytics Sedatives and Hypnotics
FDA label
Download (275 KB)
MSDS
Download (75.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentSclerosis, Progressive Systemic1
1CompletedNot AvailableHealthy Volunteers2
1CompletedNot AvailableTo Determine Bioequivalence Under Fasting Conditions1
1CompletedOtherTo Determine Bioequivalence Under Fed Conditions1
1RecruitingTreatmentDyskinesias / Movement Disorders / Parkinson's Disease (PD)1
1, 2CompletedBasic ScienceCessation, Smoking / Tobacco Use Cessation1
1, 2CompletedTreatmentAutism, Early Infantile1
1, 2CompletedTreatmentSpinal Cord Injuries (SCI)1
2CompletedBasic ScienceCannabis Use Disorders1
2CompletedBasic ScienceDependence, Cocaine1
2CompletedTreatmentAttention Deficit Disorder With Hyperactivity1
2CompletedTreatmentDependence, Cocaine1
2CompletedTreatmentHypoactive Sexual Desire Disorder (HSDD)2
2CompletedTreatmentMajor Depressive Disorder (MDD)1
2CompletedTreatmentMarijuana Abuse1
2CompletedTreatmentMarijuana Abuse / Moods Disorders1
2Not Yet RecruitingTreatmentAutism Spectrum Conditions/Disorders / Feeling Anxious1
2RecruitingBasic ScienceSleep Disordered Breathing (SDB) / Spinal Cord Injuries (SCI)1
2RecruitingTreatmentFeeling Anxious / Parkinson's Disease (PD)1
2TerminatedTreatmentAnxiety Disorders / Depression / Epilepsies / Epilepsy, Localization Related / Seizures1
2WithdrawnTreatmentAutism Spectrum Conditions/Disorders1
2, 3CompletedSupportive CareDyspnea / Pulmonary Complications / Unspecified Adult Solid Tumor, Protocol Specific1
2, 3CompletedTreatmentAutistic Disorder1
3RecruitingTreatmentAcute Ischemic Stroke (AIS)1
3RecruitingTreatmentParkinson1
3TerminatedBasic ScienceCentral Apnea / Heart Failure, Unspecified1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
4CompletedTreatmentDepression1
4CompletedTreatmentHeroin Dependence1
4CompletedTreatmentHypothermia1
4CompletedTreatmentIndigestion1
4CompletedTreatmentMarijuana Dependence1
4Enrolling by InvitationNot AvailableBypass, Gastric1
4RecruitingDiagnosticAsthma Bronchial / Asthma: [Nos] or [Attack] / Major Depressive Disorder (MDD)1
4Unknown StatusTreatmentMajor Depression Disorder1
4WithdrawnTreatmentAnxiety Disorders1
Not AvailableCompletedBasic ScienceCocaine Use Disorders1
Not AvailableCompletedTreatmentFunctional Dysphagia / Ineffective Esophageal Motility1
Not AvailableEnrolling by InvitationNot AvailableCardiovascular Disease (CVD) / Cardiovascular Risk Factors / High Blood Pressure (Hypertension) / Mental status changes / Sleep Apnea Syndrome / Sleep Bruxism / Sleep disorders and disturbances / Temporomandibular Disorders / Thyroid Dysfunction1
Not AvailableRecruitingTreatmentAutism Spectrum Conditions/Disorders / Feeling Anxious1
Not AvailableRecruitingTreatmentTraumatic Brain Injury (TBI)1
Not AvailableUnknown StatusTreatmentAnxiety Disorders1

Pharmacoeconomics

Manufacturers
  • Bristol myers squibb co pharmaceutical research institute
  • Actavis totowa llc
  • Apotex inc
  • Dr reddys laboratories ltd
  • Egis pharmaceuticals
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Kv pharmaceutical co
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
Packagers
  • Advanced Pharmaceutical Services Inc.
  • Amerisource Health Services Corp.
  • Apotex Inc.
  • Apotheca Inc.
  • Apothecon
  • AQ Pharmaceuticals Inc.
  • A-S Medication Solutions LLC
  • Bristol-Myers Squibb Co.
  • Bryant Ranch Prepack
  • BTA Pharmaceuticals
  • Cardinal Health
  • Comprehensive Consultant Services Inc.
  • Corepharma LLC
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Doctor Reddys Laboratories Ltd.
  • Egis Pharmaceuticals Public Ltd. Co.
  • Ethex Corp.
  • H.E. Butt Grocery Co.
  • Heartland Repack Services LLC
  • Innoviant Pharmacy Inc.
  • Ivax Pharmaceuticals
  • KV Pharmaceutical Co.
  • Lake Erie Medical and Surgical Supply
  • Major Pharmaceuticals
  • Mckesson Corp.
  • Medisca Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Neuman Distributors Inc.
  • Nucare Pharmaceuticals Inc.
  • Palmetto Pharmaceuticals Inc.
  • Par Pharmaceuticals
  • Patheon Inc.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Prx Pharmaceuticals
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Sandhills Packaging Inc.
  • Southwood Pharmaceuticals
  • Stat Rx Usa
  • Teva Pharmaceutical Industries Ltd.
  • Torpharm Inc.
  • UDL Laboratories
  • Va Cmop Dallas
  • Vangard Labs Inc.
  • Watson Pharmaceuticals
Dosage forms
FormRouteStrength
TabletOral10 mg
TabletOral10 mg/1
TabletOral15 mg/1
TabletOral30 mg/1
TabletOral5 mg/1
TabletOral7.5 mg/1
TabletOral5 mg
Prices
Unit descriptionCostUnit
Wellbutrin xl 300 mg tablet8.68USD tablet
Wellbutrin xl 150 mg tablet6.58USD tablet
Buspar 30 mg tablet5.52USD tablet
Buspirone hcl powder4.74USD g
Buspirone hcl 30 mg tablet3.71USD tablet
Buspar 15 mg tablet3.07USD tablet
Buspirone hcl 15 mg tablet2.16USD tablet
Buspar 10 mg tablet2.05USD tablet
Buspirone hcl 7.5 mg tablet1.62USD tablet
Buspirone hcl 10 mg tablet1.42USD tablet
Buspar 5 mg tablet1.18USD tablet
Vanspar 7.5 mg tablet1.18USD tablet
Buspar 10 mg Tablet1.12USD tablet
Buspirone hcl 5 mg tablet0.79USD tablet
Apo-Buspirone 10 mg Tablet0.62USD tablet
Novo-Buspirone 10 mg Tablet0.62USD tablet
Nu-Buspirone 10 mg Tablet0.62USD tablet
Pms-Buspirone 10 mg Tablet0.62USD tablet
Ratio-Buspirone 10 mg Tablet0.62USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)201.5-202.5 °CNot Available
water solubility21.4 mg/LNot Available
logP2.63TAKACS-NOVAK,K 1995 (IN PRESS)
Predicted Properties
PropertyValueSource
Water Solubility0.588 mg/mLALOGPS
logP1.95ALOGPS
logP1.78ChemAxon
logS-2.8ALOGPS
pKa (Strongest Basic)7.62ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area69.64 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity108.89 m3·mol-1ChemAxon
Polarizability44.12 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9935
Blood Brain Barrier+0.9839
Caco-2 permeable-0.538
P-glycoprotein substrateSubstrate0.5726
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IINon-inhibitor0.8282
Renal organic cation transporterInhibitor0.598
CYP450 2C9 substrateNon-substrate0.8703
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.6728
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorInhibitor0.8948
CYP450 2D6 inhibitorInhibitor0.7186
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8681
Ames testNon AMES toxic0.6277
CarcinogenicityNon-carcinogens0.8959
BiodegradationNot ready biodegradable0.987
Rat acute toxicity2.8167 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7042
hERG inhibition (predictor II)Inhibitor0.6914
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-004i-6940000000-197b8ea9ac79cbda753b
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0009000000-429c277f63eb2ab52f57
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0009000000-170a03c9244dada2609b
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00di-0922000000-80c9aa9ae15b661116ad
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00di-1900000000-fafa91d49f01314afdf1
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00dj-4900000000-460409b07d20201af414
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000f-0930000000-081eac0a05abab8fc5fa

Taxonomy

Description
This compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
N-arylpiperazines
Alternative Parents
Azaspirodecane derivatives / Piperidinediones / Dialkylarylamines / Aminopyrimidines and derivatives / N-alkylpiperazines / Delta lactams / N-substituted carboxylic acid imides / Heteroaromatic compounds / Dicarboximides / Trialkylamines
show 6 more
Substituents
Azaspirodecanedione / N-arylpiperazine / Azaspirodecane / Piperidinedione / Dialkylarylamine / Aminopyrimidine / N-alkylpiperazine / Piperidinone / Delta-lactam / Pyrimidine
show 21 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
N-arylpiperazine, pyrimidines, N-alkylpiperazine, piperidones, azaspiro compound (CHEBI:3223)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Partial agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. de Boer SF, Lesourd M, Mocaer E, Koolhaas JM: Selective antiaggressive effects of alnespirone in resident-intruder test are mediated via 5-hydroxytryptamine1A receptors: A comparative pharmacological study with 8-hydroxy-2-dipropylaminotetralin, ipsapirone, buspirone, eltoprazine, and WAY-100635. J Pharmacol Exp Ther. 1999 Mar;288(3):1125-33. [PubMed:10027850]
  2. Rehman J, Kaynan A, Christ G, Valcic M, Maayani S, Melman A: Modification of sexual behavior of Long-Evans male rats by drugs acting on the 5-HT1A receptor. Brain Res. 1999 Mar 13;821(2):414-25. [PubMed:10064829]
  3. Liang KC: Pre- or post-training injection of buspirone impaired retention in the inhibitory avoidance task: involvement of amygdala 5-HT1A receptors. Eur J Neurosci. 1999 May;11(5):1491-500. [PubMed:10215901]
  4. Becker C, Hamon M, Benoliel JJ: Prevention by 5-HT1A receptor agonists of restraint stress- and yohimbine-induced release of cholecystokinin in the frontal cortex of the freely moving rat. Neuropharmacology. 1999 Apr;38(4):525-32. [PubMed:10221756]
  5. Dupuis DS, Tardif S, Wurch T, Colpaert FC, Pauwels PJ: Modulation of 5-HT1A receptor signalling by point-mutation of cysteine351 in the rat Galpha(o) protein. Neuropharmacology. 1999 Jul;38(7):1035-41. [PubMed:10428422]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  7. Osei-Owusu P, Scrogin KE: Buspirone raises blood pressure through activation of sympathetic nervous system and by direct activation of alpha1-adrenergic receptors after severe hemorrhage. J Pharmacol Exp Ther. 2004 Jun;309(3):1132-40. Epub 2004 Feb 9. [PubMed:14769835]
Details
2. D(2) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Malt EA, Olafsson S, Aakvaag A, Lund A, Ursin H: Altered dopamine D2 receptor function in fibromyalgia patients: a neuroendocrine study with buspirone in women with fibromyalgia compared to female population based controls. J Affect Disord. 2003 Jun;75(1):77-82. [PubMed:12781354]
  2. Boido A, Boido CC, Sparatore F: Synthesis and pharmacological evaluation of aryl/heteroaryl piperazinyl alkyl benzotriazoles as ligands for some serotonin and dopamine receptor subtypes. Farmaco. 2001 Apr;56(4):263-75. [PubMed:11421254]
  3. Nader MA, Hannemann M: Interactions of buspirone or gepirone with nicotine on schedule-controlled behavior of pigeons. Behav Pharmacol. 1993 Jun;4(3):263-268. [PubMed:11224194]
  4. Pache DM, Fernandez-Perez S, Sewell RD: Buspirone differentially modifies short-term memory function in a combined delayed matching/non-matching to position task. Eur J Pharmacol. 2003 Sep 23;477(3):205-11. [PubMed:14522358]
  5. Fernandez-Perez S, Pache DM, Sewell RD: Co-administration of fluoxetine and WAY100635 improves short-term memory function. Eur J Pharmacol. 2005 Oct 17;522(1-3):78-83. Epub 2005 Oct 7. [PubMed:16214127]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Zhu M, Zhao W, Jimenez H, Zhang D, Yeola S, Dai R, Vachharajani N, Mitroka J: Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab Dispos. 2005 Apr;33(4):500-7. Epub 2005 Jan 7. [PubMed:15640381]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Zhu M, Zhao W, Jimenez H, Zhang D, Yeola S, Dai R, Vachharajani N, Mitroka J: Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab Dispos. 2005 Apr;33(4):500-7. Epub 2005 Jan 7. [PubMed:15640381]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Zhu M, Zhao W, Jimenez H, Zhang D, Yeola S, Dai R, Vachharajani N, Mitroka J: Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab Dispos. 2005 Apr;33(4):500-7. Epub 2005 Jan 7. [PubMed:15640381]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524]

Drug created on June 13, 2005 07:24 / Updated on April 17, 2018 00:57